BMS-986165: Data from P2 trial (NCT03934216) for moderate-to-severe ulcerative colitis in 2021 (Bristol-Myers Squibb) - Jun 27, 2020 - Investor Series Immunology and Cardiovascular: Data from P2 trial (NCT03599622) for moderate-to-severe Crohn's disease in 2022 or later P2 data • Crohn's disease • Inflammatory Bowel Disease • Ulcerative Colitis
|